医学
心房颤动
内科学
导管消融
心脏病学
肥厚性心肌病
危险系数
不利影响
烧蚀
倾向得分匹配
心力衰竭
队列
回顾性队列研究
比例危险模型
心肌病
导管
队列研究
心脏再同步化治疗
冲程(发动机)
心电图
置信区间
生存分析
酒精间隔消融
心脏病
植入式心律转复除颤器
心源性猝死
存活率
射血分数
作者
Siddharth Agarwal,Harsh P. Patel,Rutvij M. Patel,Divya R. Patel,Naiya Mainigi,Zain Ul Abideen Asad,Muhammad Bilal Munir,Konstantinos C. Siontis,Nicholas Yick Loong Tan,Gurukripa N. Kowlgi,Freddy Del‐Carpio Munoz,Abhishek J. Deshmukh,Christopher V. DeSimone
摘要
BACKGROUND: Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and is associated with increased morbidity, heart failure (HF) exacerbations, and adverse long-term outcomes. Although catheter ablation is an established rhythm-control strategy, data comparing its long-term clinical outcomes with anti-arrhythmic drug (AAD) therapy in patients with HCM remain limited. OBJECTIVE: To compare long-term clinical outcomes of catheter ablation versus medical therapy with AADs in patients with HCM and AF. METHODS: We conducted a retrospective cohort study using the TriNetX Research Network, a global federated database of electronic health records. Adult patients with HCM and AF between January 2010 and December 2020 were identified and stratified according to treatment with catheter ablation or AAD therapy. Outcomes included all-cause mortality, HF exacerbations, AAD-related adverse events, all-cause hospitalization, ischemic stroke, repeat ablation, need for cardioversion, need for long-term AAD use, and atrioventricular nodal ablation. A 1:1 propensity score matching (PSM) analysis was performed to balance baseline characteristics. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate hazard ratios (HRs). RESULTS: After PSM, 3144 patients were included (1572 in each cohort) with a mean follow-up of approximately 3.4 years. Catheter ablation was associated with lower all-cause mortality compared with AAD therapy (9.5% vs. 14.8%; HR: 0.60; 95% CI: 0.49-0.74; p < 0.001). Ablation was also associated with reduced risk of HF exacerbations (38.4% vs. 43.3%; HR: 0.79; 95% CI: 0.71-0.88; p < 0.001) and fewer AAD-related adverse events (8.4% vs. 11.2%; HR: 0.71; 95% CI: 0.55-0.93; p = 0.011). Rates of all-cause hospitalization (HR: 0.93; p = 0.11) and ischemic stroke (HR: 0.78; p = 0.10) were similar between groups. CONCLUSION: In this large real-world cohort of patients with HCM and AF, catheter ablation was associated with lower mortality, reduced HF hospitalizations, and decreased AAD therapy-related adverse events, as compared with medical therapy. These findings suggest that catheter ablation may provide meaningful clinical benefits in selected patients with HCM and AF, although prospective studies are needed to confirm these observations.
科研通智能强力驱动
Strongly Powered by AbleSci AI